Listing of Claims

1. (Previously presented) A spray dried solid dispersion consisting of a sparingly water-soluble drug and hydroxypropyl methylcellulose acetate succinate (HPMCAS), said drug being molecularly dispersed and amorphous in said dispersion, having a drug:polymer weight ratio between 1:0.4 and 1:20, and said dispersion is a homogeneous solid solution of said drug in said HPMCAS.

2. - 3. (Canceled)

4. (Previously presented) The spray dried solid dispersion of claim 1, wherein said drug is amorphous when undispersed.

5. - 22. (Canceled)

23. (Previously presented) The spray dried solid dispersion of claim 1, in the form of particles less than 100 μm in diameter.

24. - 27. (Canceled)

28. (Withdrawn) A composition as defined in claims 1 and 15 wherein said drug is a glycogen phosphorylase inhibitor.

29. (Withdrawn) A composition as defined in claims 1 and 15 wherein said drug is



or a pharmaceutically acceptable salt thereof.

30. (Withdrawn) A composition as defined in claims 1 and 15 wherein said drug is



or a pharmaceutically acceptable salt thereof.

31. (Withdrawn) A composition as defined in claims 1 and 15 wherein said drug is a 5-lipoxygenase inhibitor.

32. (Withdrawn) A composition as defined in claims 1 and 15 wherein said drug is



or a pharmaceutically acceptable salt thereof.

33. (Withdrawn) A composition defined in claims 1 and 15 wherein said drug is a corticotropic releasing hormone (CRH) inhibitor.

34. (Withdrawn) A composition as defined in claims 1 and 15 wherein said drug is



or a pharmaceutically acceptable salt thereof.

35. (Withdrawn) A composition as defined in claims 1 and 15 wherein said drug is



or a pharmaceutically acceptable salt thereof.

36. (Previously presented) The spray dried solid dispersion of claim 1, wherein said drug is an antipsychotic.

37. (Previously presented) The spray dried solid dispersion of claim 1, wherein said drug is ziprasidone.

38. (Withdrawn) A composition as defined in claims 1 and 15 wherein said drug is selected from griseofulvin, nifedipine, and phenytoin.

39. - 48. (Canceled)

49. (Previously presented) The spray dried solid dispersion of claim 1, wherein said dispersion comprises spray dried particles that are solidified in less than 2 seconds.

50. (Previously presented) The spray dried solid dispersion of claim 1, in the form of particles having a residual solvent content less than 2 wt%.

51. (Previously presented) The spray dried solid dispersion of claim 1, in the form of spray dried particles from a solution in which the concentration of drug in the solvent is less than 20 g/100 g and in which the total solids content is less than 25 weight%.

52. (Canceled)

53. (Previously presented) The spray dried solid dispersion of claim 1, wherein said drug has a dose to aqueous solubility ratio greater than 100.

54. (Previously presented) The spray dried solid dispersion of claim 1, wherein said drug is crystalline when undispersed.

55. (Previously presented) The spray dried solid dispersion of claim 1, having a drug:polymer weight ratio between 1:0.5 and 1:20.

56. (Previously presented) The spray dried solid dispersion of claim 1, having a drug:polymer weight ratio between 1:1 and 1:20.

57. (Withdrawn) The spray dried solid dispersion of claim 1, wherein said drug is selected from the group consisting of glycogen phosphorylase inhibitors, 5-lipoxygenase inhibitors, corticotropic releasing hormone inhibitors, griseofulvin, nifedipine, and phenytoin.

58. (Previously presented) The spray dried solid dispersion of claim 1, wherein said spray dried solid dispersion is supersaturated in said drug.